Drug Patents owned by Bristol Myers Squibb
1. Drug name - ELIQUIS
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6967208 | BRISTOL MYERS SQUIBB | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors |
Nov, 2026
(4 years from now) | |
| CN101357914A | BRISTOL MYERS SQUIBB | Lactam-Containing Compounds And Derivatives Thereof As Factor Xa Inhibitors |
Apr, 2012
(10 years ago) | |
| CN1578660A | BRISTOL MYERS SQUIBB | Lactam-Containing Compounds And Derivatives Thereof As Factor Xa Inhibitors |
Sep, 2022
(15 days ago) | |
| CN1578660B | BRISTOL MYERS SQUIBB | Lactam Containing Compounds And Derivatives Thereof As Factor Xa Inhibitors |
Sep, 2022
(15 days ago) | |
| IN200400590P1 | BRISTOL MYERS SQUIBB | A Novel Compound Of Formula (1) |
Sep, 2022
(15 days ago) | |
| IN247381B | BRISTOL MYERS SQUIBB | A Novel Compound Of Formula (1) |
Sep, 2022
(15 days ago) | |
| EP2105436B1 | BRISTOL MYERS SQUIBB | Lactam-Containing Compounds And Derivatives Thereof As Factor Xa Inhibitors |
Sep, 2022
(15 days ago) | |
| EP2105436A1 | BRISTOL MYERS SQUIBB | Lactam-Containing Compounds And Derivatives Thereof As Factor Xa Inhibitors |
Sep, 2022
(15 days ago) | |
| EP1427415A1 | BRISTOL MYERS SQUIBB | Lactam-Containing Compounds And Derivatives Thereof As Factor Xa Inhibitors |
May, 2026
(3 years from now) | |
| EP1427415B1 | BRISTOL MYERS SQUIBB | Lactam-Containing Compounds And Derivatives Thereof As Factor Xa Inhibitors |
May, 2026
(3 years from now) | |
| EP1427415A4 | BRISTOL MYERS SQUIBB | Lactam-Containing Compounds And Derivatives Thereof As Factor Xa Inhibitors |
May, 2026
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9326945 | BRISTOL MYERS SQUIBB | Apixaban formulations |
Feb, 2031
(8 years from now) | |
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 2.5MG | TABLET;ORAL | Prescription |
| 5MG | TABLET;ORAL | Prescription |
2. Drug name - SPRYCEL
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7491725 | BRISTOL MYERS SQUIBB | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
Mar, 2026
(3 years from now) | |
| CN1980909B | BRISTOL MYERS SQUIBB | As Kinase Inhibitor 2-Amino Thiazole -5 - Aromatic Methanamide Preparation Method |
Feb, 2022
(7 months ago) | |
| CN1980909A | BRISTOL MYERS SQUIBB | Preparation Method Of 2-Aminothiazole-5-Aromatic Methanamide Regarded As Kinase Inhibiter |
Feb, 2022
(7 months ago) | |
| EP1711481A2 | BRISTOL MYERS SQUIBB | Process For Preparing 2-Aminothiazole-5-Aromatic Carboxamides As Kinase Inhibitors |
Feb, 2025
(2 years from now) | |
| EP1711481B2 | BRISTOL MYERS SQUIBB | Crystalline Monohydrate As Kinase Inhibitors |
Feb, 2025
(2 years from now) | |
| EP1711481B1 | BRISTOL MYERS SQUIBB | Crystalline Monohydrate As Kinase Inhibitors |
Feb, 2025
(2 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8680103 | BRISTOL MYERS SQUIBB | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
Feb, 2025
(2 years from now) | |
|
US8680103
(Pediatric) | BRISTOL MYERS SQUIBB | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
Aug, 2025
(2 years from now) | |
|
US7491725
(Pediatric) | BRISTOL MYERS SQUIBB | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
Sep, 2026
(3 years from now) | |
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 20MG | TABLET;ORAL | Prescription |
| 50MG | TABLET;ORAL | Prescription |
| 70MG | TABLET;ORAL | Prescription |
| 80MG | TABLET;ORAL | Prescription |
| 100MG | TABLET;ORAL | Prescription |
| 140MG | TABLET;ORAL | Prescription |
3. Drug name - ZERIT XR
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7135465 | BRISTOL MYERS SQUIBB | Sustained release beadlets containing stavudine |
Feb, 2023
(4 months from now) | |
|
US7135465
(Pediatric) | BRISTOL MYERS SQUIBB | Sustained release beadlets containing stavudine |
Aug, 2023
(10 months from now) | |
Drugs and Companies using STAVUDINE ingredient
Treatment: Method for treating hiv-1 infection
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 37.5MG | CAPSULE, EXTENDED RELEASE;ORAL | Discontinued |
| 50MG | CAPSULE, EXTENDED RELEASE;ORAL | Discontinued |
| 75MG | CAPSULE, EXTENDED RELEASE;ORAL | Discontinued |
| 100MG | CAPSULE, EXTENDED RELEASE;ORAL | Discontinued |
availability in other generic markets.
Click on the highlighted region to filter.